Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

VolitionRX Limited VNRX

Healthcare  —  Medical Devices
0.26 0.01 4.00% as of 25 Sep
Market cap
$6.9M
P/E
0.0×
Revenue Champion (5y) Insider Buys (last 12m)
Growth Flags show if company had growth for consecutive years,
Insider Buys alert about insiders buying in the last 12 month
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

VolitionRX Limited (VNRX) Business Profile

Updated before January 2025

Company Overview

VolitionRX Limited (VNRX) is a biotechnology company specializing in the development of simple, cost-effective blood tests for the diagnosis and monitoring of a range of diseases, with a primary focus on cancer diagnostics. Founded in 2010, the company is headquartered in Austin, Texas, with additional operational facilities in Belgium and Singapore. VolitionRX is led by an experienced leadership team, including Cameron Reynolds, who serves as the President and Chief Executive Officer. The company’s mission is to revolutionize disease diagnostics through its proprietary Nu.Q® technology platform, which leverages epigenetic and nucleosome-based biomarkers.

Core Business Segments

Nu.Q® Technology Platform

The cornerstone of VolitionRX’s product portfolio is its Nu.Q® technology platform. This innovative platform is designed to detect and measure nucleosomes in the bloodstream, which are indicative of various diseases, including cancer, inflammatory conditions, and infectious diseases. Key products and services under this segment include:

  • Nu.Q® Cancer Tests: Blood-based diagnostic tests aimed at early detection of cancers such as colorectal, lung, and pancreatic cancer.
  • Nu.Q® Vet: A veterinary diagnostic tool designed to detect cancer and other diseases in animals, particularly dogs.
  • Nu.Q® NETs: Tests targeting neutrophil extracellular traps (NETs), which are associated with sepsis, COVID-19, and other inflammatory diseases.

Research and Development Services

VolitionRX also offers R&D services to pharmaceutical companies and academic institutions. These services include biomarker discovery, assay development, and clinical trial support, leveraging the company’s expertise in epigenetics and nucleosome biology.

Licensing and Partnerships

The company actively engages in licensing agreements and partnerships to expand the reach of its technology. These collaborations enable VolitionRX to integrate its diagnostic solutions into broader healthcare ecosystems.

Business Model

VolitionRX operates on a hybrid business model that combines product sales, service offerings, and strategic partnerships. Revenue is primarily generated through the sale of diagnostic tests, licensing fees, and collaborative R&D agreements. The company’s approach emphasizes scalability and accessibility, ensuring that its diagnostic solutions are affordable and widely available. By focusing on non-invasive, blood-based tests, VolitionRX aims to reduce the barriers to early disease detection and improve patient outcomes.

Strategic Direction

VolitionRX is committed to expanding its product portfolio and entering new markets. Key strategic initiatives include:

  • Global Expansion: The company is actively pursuing regulatory approvals in multiple regions, including the United States, Europe, and Asia, to broaden the availability of its Nu.Q® tests.
  • Product Innovation: Ongoing R&D efforts are focused on developing new applications for the Nu.Q® platform, including tests for neurodegenerative diseases and cardiovascular conditions.
  • Sustainability Goals: VolitionRX is dedicated to minimizing its environmental footprint by adopting sustainable practices in its manufacturing and operational processes.
  • Veterinary Diagnostics Growth: The Nu.Q® Vet segment is a significant growth area, with plans to expand its market presence in the veterinary diagnostics industry.

Competitive Landscape

VolitionRX operates in a highly competitive biotechnology and diagnostics market. Key competitors include:

  • Exact Sciences Corporation: Known for its Cologuard® test for colorectal cancer screening.
  • Guardant Health: Specializes in liquid biopsy tests for cancer detection.
  • Bio-Rad Laboratories: Offers a range of diagnostic and research tools, including cancer biomarkers.
  • IDEXX Laboratories: A leader in veterinary diagnostics, competing with VolitionRX’s Nu.Q® Vet products.

Despite the competition, VolitionRX differentiates itself through its proprietary Nu.Q® technology, which offers a unique approach to disease diagnostics.

Risk Factors

VolitionRX faces several risks that could impact its operations and financial performance:

  • Regulatory Challenges: Obtaining and maintaining regulatory approvals for its products in different regions can be time-consuming and costly.
  • Market Dependence: The company’s success is heavily reliant on the adoption of its Nu.Q® tests by healthcare providers and consumers.
  • Supply Chain Disruptions: Dependence on third-party suppliers for raw materials and manufacturing could lead to delays or increased costs.
  • Competitive Pressure: The diagnostics market is highly competitive, with numerous established players and new entrants.
  • R&D Uncertainty: The development of new diagnostic tests involves significant investment and carries the risk of failure.

Recent Developments

  • Nu.Q® Vet Launch: VolitionRX recently launched its Nu.Q® Vet Cancer Screening Test in the United States, targeting the veterinary diagnostics market.
  • COVID-19 Applications: The company has expanded its Nu.Q® NETs platform to include applications for monitoring COVID-19 severity and progression.
  • Strategic Partnerships: VolitionRX has entered into collaborations with leading pharmaceutical companies to explore new applications for its technology.
  • Regulatory Milestones: The company has achieved CE marking for several of its Nu.Q® tests, enabling their commercialization in the European Union.

Investment Considerations

Strengths

  • Innovative Technology: The Nu.Q® platform offers a unique, non-invasive approach to disease diagnostics.
  • Diverse Applications: The technology is applicable to a wide range of diseases, including cancer, inflammatory conditions, and infectious diseases.
  • Veterinary Market Potential: The Nu.Q® Vet segment represents a significant growth opportunity.
  • Global Reach: The company’s presence in multiple regions positions it for international growth.

Risks

  • Financial Performance: As a growth-stage company, VolitionRX may face challenges in achieving profitability.
  • Regulatory Hurdles: Delays in obtaining regulatory approvals could impact product launches.
  • Market Competition: The diagnostics market is crowded, with numerous competitors offering alternative solutions.

Conclusion

VolitionRX Limited is a pioneering biotechnology company with a strong focus on revolutionizing disease diagnostics through its innovative Nu.Q® technology platform. With a diverse product portfolio, strategic growth initiatives, and a commitment to sustainability, the company is well-positioned to capitalize on emerging opportunities in the diagnostics and veterinary markets. However, investors should carefully consider the associated risks, including regulatory challenges and market competition. Overall, VolitionRX’s unique approach and global expansion efforts make it a compelling player in the biotechnology sector.